Delymer - Novel polymer-based nanoparticles for targeted delivery and controlled release of gene therapy and immunotherapy.
Although gene therapies bare a great potential as therapeutic modality its clinical development is halted due to inadequate delivery systems. To date, the most common delivery systems are virus-based, which have limited scalability and concern about the safety of repeated administration.
We have developed a machine learning algorithm for optimization of biocompatible polymer nanoparticle composition, tailored for a unique payload and a specific target tissue. Using our algorithm we will offer polymer-based nanoparticles that will allow delivery of large payloads, multiple dosing, while being targeted to specific tissues. Thus, we can maximize the delivery of large complex macromolecules, such as Cas9 protein with guide RNA, large nucleic polymers, such as DNA or RNA of therapeutic genes or engineered antibodies to the site where immunotherapy is needed to increase their accumulation within the target site, and reduce adverse effects. The controlled release is enabled by ultrasound or pH change. Our Company is a partnership based business with a goal to enhance the treatments gene/cell therapy companies are working on.
Although gene therapies bare a great potential as therapeutic modality its clinical development is halted due to inadequate delivery systems. To date, the most common delivery systems are virus-based, which have limited scalability and concern about the safety of repeated administration.
We have developed a machine learning algorithm for optimization of biocompatible polymer nanoparticle composition, tailored for a unique payload and a specific target tissue. Using our algorithm we will offer polymer-based nanoparticles that will allow delivery of large payloads, multiple dosing, while being targeted to specific tissues. Thus, we can maximize the delivery of large complex macromolecules, such as Cas9 protein with guide RNA, large nucleic polymers, such as DNA or RNA of therapeutic genes or engineered antibodies to the site where immunotherapy is needed to increase their accumulation within the target site, and reduce adverse effects. The controlled release is enabled by ultrasound or pH change. Our Company is a partnership based business with a goal to enhance the treatments gene/cell therapy companies are working on.
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
